Immune characterization of the HBHA-specific response in mycobacterium tuberculosis-infected patients with or without HIV infection

PLoS ONE

Volumn 12, Issue 8, 2017, Pages

  Chiacchio, Teresa ^a   Delogu, Giovanni ^b   Vanini, Valentina ^a   Cuzzi, Gilda ^a   De Maio, Flavio ^b   Pinnetti, Carmela ^a   Sampaolesi, Alessandro ^a   Antinori, Andrea ^a   Goletti, Delia ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; HEMAGGLUTININ; HEPARIN BINDING HEMAGGLUTININ; HEPARIN BINDING PROTEIN; INTERLEUKIN 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; HEPARIN-BINDING HEMAGGLUTININ; LECTIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EFFECTOR CELL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; INFECTION RISK; LUNG TUBERCULOSIS; MALE; MEMORY CELL; MYCOBACTERIUM SMEGMATIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; BIOSYNTHESIS; COMPLICATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; METABOLISM; MIDDLE AGED; PATHOLOGY; TUBERCULOSIS;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; LECTINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUBERCULOSIS;

EID: 85028413783     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0183846     Document Type: Article

References (50)

1. World Health Organization. Global Tuberculosis Report 2016. 2016.
2. Pokrovskiy V. HIV epidemic in Russia and neighbouring countries. J.Int.AIDS Soc. 2014; 17:19502. https://doi.org/10.7448/IAS.17.4.19502 PMID: 25394011
3. Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A, et al. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. Lancet HIV. 2016; 3:e120–e131. https://doi.org/10.1016/S2352-3018(15)00252-0 PMID: 26939735
4. Ronacher K, Joosten SA, Van CR, Dockrell HM, Walzl G, Ottenhoff TH. Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. Immunol.Rev. 2015; 264:121–37. https://doi.org/10.1111/imr.12257 PMID: 25703556
5. Diedrich CR, Flynn JL. HIV-1/mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis? Infect.Immun. 2011; 79:1407–17. https://doi.org/10.1128/IAI.01126-10PMID: 21245275
6. Nusbaum RJ, Calderon VE, Huante MB, Sutjita P, Vijayakumar S, Lancaster KL, et al. Pulmonary Tuberculosis in Humanized Mice Infected with HIV-1. Sci.Rep. 2016; 6:21522. https://doi.org/10.1038/ srep21522 PMID: 26908312
7. Pollock KM, Montamat-Sicotte DJ, Grass L, Cooke GS, Kapembwa MS, Kon OM, et al. PD-1 Expression and Cytokine Secretion Profiles of Mycobacterium tuberculosis-Specific CD4+ T-Cell Subsets; Potential Correlates of Containment in HIV-TB Co-Infection. PLoS.ONE. 2016; 11:e0146905. https://doi.org/10.1371/journal.pone.0146905 PMID: 26756579
8. Houben RM, Crampin AC, Ndhlovu R, Sonnenberg P, Godfrey-Faussett P, Haas WH, et al. Human immunodeficiency virus associated tuberculosis more often due to recent infection than reactivation of latent infection. Int.J.Tuberc.Lung Dis. 2011; 15:24–31. PMID: 21276292
9. Goletti D, Sanduzzi A, Delogu G. Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J.Rheumatol.Suppl 2014; 91:24–31. https://doi.org/10.3899/jrheum.140099 PMID: 24788997
10. Goletti D, Carrara S, Mayanja-Kizza H, Baseke J, Mugerwa MA, Girardi E, et al. Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. BMC.Infect.Dis. 2008; 8:11. https://doi.org/10.1186/1471-2334-8-11 PMID: 18226199
11. Vincenti D, Carrara S, Butera O, Bizzoni F, Casetti R, Girardi E, et al. Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. Clin.Exp.Immunol. 2007; 150:91–8. https://doi.org/10.1111/j.13652249.2007.03462.x PMID: 17680823
12. Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am.J.Respir.Crit Care Med. 2014; 190:1168–76. https://doi.org/10.1164/rccm.201405-0967OC PMID: 25303140
13. Launois P, Drowart A, Bourreau E, Couppie P, Farber CM, Van Vooren JP, et al. T cell reactivity against mycolyl transferase antigen 85 of M. tuberculosis in HIV-TB coinfected subjects and in AIDS patients suffering from tuberculosis and nontuberculous mycobacterial infections. Clin.Dev.Immunol. 2011; 2011.
14. Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur.Respir.J. 2016; 48:1751–63. https://doi.org/10.1183/13993003.01012-2016 PMID: 27836953
15. Vanini V, Petruccioli E, Gioia C, Cuzzi G, Orchi N, Rianda A, et al. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. J.Infect. 2012; 65:49–59. https://doi.org/10.1016/j.jinf.2012.03.017 PMID: 22465752
16. Masungi C, Temmerman S, Van Vooren JP, Drowart A, Pethe K, Menozzi FD et al. Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J.Infect.Dis. 2002; 185:513–20. https://doi.org/10.1086/338833 PMID: 11865404
17. Temmerman S, Pethe K, Parra M, Alonso S, Rouanet C, Pickett T, et al. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat.Med. 2004; 10:935–41. https://doi.org/10.1038/nm1090 PMID: 15300244
18. Zanetti S, Bua A, Delogu G, Pusceddu C, Mura M, Saba F, et al. Patients with pulmonary tuberculosis develop a strong humoral response against methylated heparin-binding hemagglutinin. Clin.Diagn.Lab Immunol. 2005; 12:1135–8. https://doi.org/10.1128/CDLI.12.9.1135-1138.2005 PMID: 16148186
19. Delogu G, Chiacchio T, Vanini V, Butera O, Cuzzi G, Bua A, et al. Methylated HBHA produced in M. smegmatis Discriminates between Active and Non-Active Tuberculosis Disease among RD1-Respond-ers. PLoS.ONE. 2011; 6:e1815.
20. Belay M, Legesse M, Mihret A, Ottenhoff TH, Franken KL, Bjune G, et al. IFN-gamma and IgA against non-methylated heparin-binding hemagglutinin as markers of protective immunity and latent tuberculosis: Results of a longitudinal study from an endemic setting. J.Infect. 2016; 72:189–200. https://doi.org/10.1016/j.jinf.2015.09.040 PMID: 26518056
21. Delogu G, Vanini V, Cuzzi G, Chiacchio T, De Maio F, Battah B, et al. Lack of Response to HBHA in HIV-Infected Patients with Latent Tuberculosis Infection. Scand.J.Immunol. 2016; 84:344–52. https://doi.org/10.1111/sji.12493 PMID: 27636597
22. Delogu G., Bua A, Pusceddu C, Parra M, Fadda G, Brennan MJ, et al. Expression and Purification of Recombinant Methylated HBHA in Mycobacterium smegmatis. FEMS Microbiol.Lett. 2004; 239:33–9. https://doi.org/10.1016/j.femsle.2004.08.015 PMID: 15451098
23. Temmerman ST, Place S, Debrie AS, Locht C, Mascart F. Effector functions of heparin-binding hemagglutinin-specific CD8+ T lymphocytes in latent human tuberculosis. J.Infect.Dis. 2005; 192:226–32. https://doi.org/10.1086/430930 PMID: 15962217
24. Goletti D, Parracino MP, Butera O, Bizzoni F, Casetti R, Dainotto D, et al. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir.Res. 2007; 8:5. https://doi.org/10.1186/1465-9921-8-5 PMID: 17257436
25. Goletti D, Raja A, Syed Ahamed KB, Rodrigues C, Sodha A, Carrara S, et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS.ONE. 2010; 5: e12577. https://doi.org/10.1371/journal.pone.0012577 PMID: 20830287
26. Petruccioli E, Petrone L, Vanini V, Sampaolesi A, Gualano G, Girardi E, et al. IFNgamma/TNFalpha specific-cells and effector memory phenotype associate with active tuberculosis. J.Infect. 2013; 66:475–86. https://doi.org/10.1016/j.jinf.2013.02.004 PMID: 23462597
27. Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Pinnetti C, Sampaolesi A, et al. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. J.Infect. 2014; 69:533–45. https://doi.org/10.1016/j.jinf.2014.06.009 PMID: 24975174
28. Wyndham-Thomas C, Corbiere V, Dirix V, Smits K, Domont F, Libin M, et al. Key role of effector memory CD4+ T lymphocytes in a short-incubation heparin-binding hemagglutinin gamma interferon release assay for the detection of latent tuberculosis. Clin.Vaccine Immunol. 2014; 21:321–8. https://doi.org/10.1128/CVI.00651-13 PMID: 24391135
29. Mascart F, Locht C. Integrating knowledge of Mycobacterium tuberculosis pathogenesis for the design of better vaccines. Expert.Rev.Vaccines. 2015; 14:1573–85. https://doi.org/10.1586/14760584.2015. 1102638 PMID: 26517361
30. Smits K, Corbiere V, Dirix V, Mekkaoui L, Wyndham-Thomas C, Libin M, et al. Immunological signatures identifying different stages of latent Mycobacterium tuberculosis infection and discriminating latent from active tuberculosis in humans. Journal of Clinical & Cellular Immunology 2015; 6:341.
31. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J.Exp.Med. 1993; 178:2249–54. PMID: 7504064
32. Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, Nicod LP, et al. Dominant TNF-alpha(+) Mycobacterium tuberculosis-specific CD4(+) T cell responses discriminate between latent infection and active disease. Nat.Med. 2011; 17:372–6. https://doi.org/10.1038/nm.2299 PMID: 21336285
33. Day CL, Abrahams DA, Lerumo L, Janse van Rensburg E, Stone L, O’rie T, et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J.Immunol. 2011; 187:2222–32. https://doi.org/10.4049/jimmunol.1101122 PMID: 21775682
34. Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, Titone L, et al. Multifunctional CD4(+) T-cells correlate with active Mycobacterium tuberculosis infection. Eur.J.Immunol. 2010; 40:2211–20. https://doi.org/10.1002/eji.201040455 PMID: 20540114
35. Wilkinson KA, Wilkinson RJ. Polyfunctional T-cells in human tuberculosis. Eur.J.Immunol. 2010; 40:2139–42. https://doi.org/10.1002/eji.201040731 PMID: 20853500
36. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013; 381:1021–8. https://doi.org/10.1016/S0140-6736(13)60177-4 PMID: 23391465
37. Day CL, Mkhwanazi N, Reddy S, Mncube Z, van der Stok M, Klenerman P, et al. Detection of polyfunctional Mycobacterium tuberculosis-specific T-cells and association with viral load in HIV-1-infected persons. J.Infect.Dis. 2008; 197:990–9. https://doi.org/10.1086/529048 PMID: 18419535
38. Pollock KM, Whitworth HS, Montamat-Sicotte DJ, Grass L, Cooke GS, Kapembwa MS, et al. T-cell immunophenotyping distinguishes active from latent tuberculosis. J.Infect.Dis. 2013; 208:952–68. https://doi.org/10.1093/infdis/jit265 PMID: 23966657
39. Beveridge NE, Fletcher HA, Hughes J, Pathan AA, Scriba TJ, Minassian A, et al. A comparison of IFNgamma detection methods used in tuberculosis vaccine trials. Tuberculosis.(Edinb.) 2008; 88:631–40.
40. Parra M, Pickett T, Delogu G, Dheenadhayalan V, Debrie AS, Locht C, et al. The Mycobacterial Heparin-binding Hemagglutinin is a Protective antigen in the Mouse Aerosol Challenge Model of Tuberculosis. Infect.Immun. 2004; 72:6799–805. https://doi.org/10.1128/IAI.72.12.6799-6805.2004 PMID: 15557600
41. Stylianou E, Diogo GR, Pepponi I, van Dolleweerd C, Arias MA, Locht C, et al. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice. Eur.J.Immunol. 2014; 44:440–9. https://doi.org/10.1002/eji.201343887 PMID: 24214530
42. Wyndham-Thomas C, Dirix V, Schepers K, Martin C, Hildebrand M, Goffard JC, et al. Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the Quanti-FERON-TB Gold In-tube. BMC.Infect.Dis. 2015; 15:59. https://doi.org/10.1186/s12879-015-0796-0PMID: 25886172
43. Lewinsohn DA, Heinzel AS, Gardner JM, Zhu L, Alderson MR, Lewinsohn DM. Mycobacterium tuberculosis-specific CD8+ T-cells preferentially recognize heavily infected cells. Am.J.Respir.Crit Care Med. 2003; 168:1346–52. https://doi.org/10.1164/rccm.200306-837OC PMID: 12969871
44. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, et al. An antimicrobial activity of cytolytic T-cells mediated by granulysin. Science 1998; 282:121–5. PMID: 9756476
45. Petruccioli E, Chiacchio T, Pepponi I, Vanini V, Urso R, Cuzzi G, et al. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. J.Infect. 2016; 73:588–97. https://doi.org/10.1016/j.jinf.2016.09.008 PMID: 27717779
46. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur.Respir.J. 2015; 46:1563–76. https://doi.org/10.1183/13993003.01245-2015 PMID: 26405286
47. Corbiere V, Pottier G, Bonkain F, Schepers K, Verscheure V, Lecher S, et al. Risk stratification of latent tuberculosis defined by combined interferon gamma release assays. PLoS.ONE. 2012; 7:e43285. https://doi.org/10.1371/journal.pone.0043285 PMID: 22912846
48. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur.Respir.J. 2009; 33:956–73. https://doi.org/10.1183/09031936.00120908 PMID: 19407047
49. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur.Respir.J. 2011; 37:100–11. https://doi.org/10.1183/09031936.00114810 PMID: 20847080
50. Petruccioli E, Vanini V, Chiacchio T, Cuzzi G, Cirillo DM, Palmieri F, et al. Analytical evaluation of Quan-tiFERON-Plus and QuantiFERON-Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis. 2017 Sep; 106:38–43. https://doi.org/10.1016/j.tube.2017.06.002 PMID: 28802403